SH3765 / Nanjing Sanhome Pharma - LARVOL DELTA

Evaluation of the safety and efficacy of SH3765 in combination with fulvestrant in HR+/HER2− advanced breast cancer: a phase Ib study (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd.

New P1 trial • Breast Cancer • Hepatocellular Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma. (PubMed, Cancer Lett) - "Moreover, PRMT5 inhibitors including SH3765 and EPZ015666 worked through blocking SREBP1/2 and FASN expression in MCL. Furthermore, PRMT5 was significantly associated with MYC expression in 105 MCL samples and the GEO database (GSE93291). CRISPR MYC knockout indicated PRMT5 can promote MCL outgrowth by inducing SREBP1/2 and FASN expression through the MYC pathway."

Journal • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Oncology • FASN • MYC • PRMT5